Study summary
Bempikibart, a non-JAK injection, showed early hair regrowth
What was tested
Bempikibart, an antibody that blocks IL-7 and TSLP signaling, in a phase 2a trial for severe alopecia areata.
What they found
- Q32 Bio reported positive regrowth results at 36 weeks.
- The FDA granted Fast Track designation.
What it means
A possible non-JAK option for people who cannot take JAK pills. Small and early.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.